Introduction {#S0001}
============

Transanal endoscopic microsurgery (TEM) was devised in an animal model by Buess *et al*. in 1983 as an alternative to transanal excision (TAE) \[[@CIT0001]\]. The use of TEM is increasing due to the ability to perform minimally invasive local treatment with large full-thickness local excision under improved vision. It has a well-established role in removal of rectal adenomas \[[@CIT0002]--[@CIT0004]\], but its purpose in local treatment of early rectal cancer is yet to be defined. The TEM is comparable to radical resection in terms of recurrence but with far less morbidity and mortality in favorable T1 tumors \[[@CIT0005]--[@CIT0007]\]. The requirement of costly equipment and difficult tumor selection remain the major drawbacks of this method, although they have to be weighed against improved functional outcomes and quality of life compared to radical resection \[[@CIT0006], [@CIT0008]\].

Aim {#S0002}
===

The aim of this study was to evaluate single center experience with TEM for early rectal cancer (defined as T1-T2 rectal cancer without any nodal involvement (N0)).

Material and methods {#S0003}
====================

From 19.02.2010 to 26.11.2013 a total of 20 patients ([Table I](#T0001){ref-type="table"}) underwent TEM for early rectal cancer. Nine were women and 11 men, age range 39 to 88 years (median: 71 years). Rectal lesions were from 10 mm to 30 mm in diameter (median 23.5 mm). Nine (45%) tumors were located in the lower third of the rectum, 10 (50%) in the middle third and 1 (5%) in the upper third. All patients underwent pelvic magnetic resonance imaging (MRI) and endorectal ultrasound, as well as abdominal ultrasound and chest X-ray preoperatively.

###### 

Patient characteristics

  No.   Age \[years\]; gender   Location in the rectum   Size of tumor \[mm\]   Pathological T stage   Histological grading, other features   Length of stay \[days\]   Adjuvant chemoradiothe-rapy   Follow--up \[months\]   Outcome
  ----- ----------------------- ------------------------ ---------------------- ---------------------- -------------------------------------- ------------------------- ----------------------------- ----------------------- -------------------------------------------------
  1     75; M                   Middle 1/3               30                     pT2                    G2                                     4                         Yes                           24                      Alive, disease free
  2     60; F                   Upper 1/3                10                     pT1                    G2                                     5                         No                            35                      Alive, disease free after immediate partial TME
  3     67; M                   Lower 1/3                30                     pT2                    G2                                     10                        Yes                           32                      Alive, disease free
  4     64; F                   Middle 1/3               20                     pT1                    G1                                     6                         No                            30                      Alive, disease free
  5     67; F                   Middle 1/3               12                     pT2                    G2                                     4                         Yes                           28                      Alive, disease free
  6     52; M                   Middle 1/3               25                     pT1                    G1[\*](#TF0001){ref-type="table-fn"}   3                         Lost to follow-up             N/A                     Lost to follow-up
  7     88; M                   Middle 1/3               17                     pT2                    G2                                     9                         Refused                       16                      Alive, disease free
  8     82; M                   Lower 1/3                29                     pT1                    G2[\*](#TF0001){ref-type="table-fn"}   4                         Yes                           14                      Alive, local recurrence, underwent salvage APR
  9     70; M                   Lower 1/3                30                     pT1                    G2                                     2                         No                            32                      Alive, disease free
  10    69; M                   Lower 1/3                28                     pT1                    G2                                     5                         No                            27                      Alive, disease free
  11    79; F                   Middle 1/3               N/A                    pT1                    G2                                     3                         No                            25                      Alive, disease free
  12    88; F                   Middle 1/3               N/A                    pT1                    G2                                     6                         No                            14                      Alive, disease free
  13    72; M                   Lower 1/3                27                     pT2                    G1                                     3                         Yes                           21                      Alive, disease free, after immediate APR
  14    78; F                   Lower 1/3                14                     pT1                    G2                                     9                         No                            21                      Alive, disease free
  15    60; F                   Middle 1/3               30                     pT1                    G2                                     9                         No                            16                      Alive, disease free
  16    82; M                   Lower 1/3                22                     pT2                    G2                                     15                        Yes                           13                      Alive, disease free
  17    39; F                   Lower 1/3                20                     pT1                    G2[\*](#TF0001){ref-type="table-fn"}   2                         Yes                           10                      Alive, disease free, after immediate APR
  18    59; F                   Lower 1/3                22                     pT1                    G2                                     3                         No                            10                      Alive, disease free
  19    72; M                   Middle 1/3               10                     pT1                    G1                                     4                         No                            5                       Alive, disease free
  20    72; M                   Middle 1/3               30                     pT1                    G1                                     4                         No                            2                       Alive, disease free

M -- male, F -- female

Lymphovascular invasion

All patients who underwent rectal adenocarcinoma were offered TEM as an alternative to open total mesorectal excision (TME). Selection criteria for TEM were well or moderately differentiated T1 rectal cancer without any nodal involvement (N0) and no histological signs of poor prognosis on preoperative biopsy. Two patients (an 88-year-old patient (case no. 7) and an 82-year-old patient (case no. 16)) were found to have T2N1 rectal cancer on MRI -- due to refusal of radical resection and presence of significant co-morbidities TEM was performed.

All operations were performed under general anesthesia, in lithotomy, prone jack-knife, left lateral or right lateral position (depending on the exact location of the tumor). Standard TEM equipment was used. Full thickness excision with 1 cm safety margin was attempted, followed by closing of the rectal wall defect in one-layer running monocryl 3-0 suture using silver clips. In one case (TEM was performed for T2 rectal cancer), the abdominal cavity was penetrated and two-layer closure was preferred.

One patient (case no. 10) with pT1 rectal cancer had co-existing stage II G3 peripheral lung cancer, which was treated by lower left lobectomy and chemoradiotherapy in 2010.

The postoperative surveillance protocol, which includes rigid proctoscopy, carcinoembryonic antigen (CEA) and endorectal ultrasound every 3 months during the first 2 years, was applied to all patients after TEM.

Results {#S0004}
=======

Final histology revealed 14 (70%) lesions to be T1 and 6 (30%) T2 cancers. Five (25%) tumors were well differentiated (G1), and the remaining 15 (75%) were moderately differentiated (G2). In all 20 cases resection margins were adequate and disease-free. Operative time ranged from 30 to 300 min (median: 72.5 min). Median length of stay was 4 days (range: 2--15 days).

Postoperative recovery was uneventful in all cases. One patient in the pT1 group (case no. 2) underwent TEM for an upper 1/3 polyp which was understaged preoperatively as *carcinoma in situ*, and open partial TME was proposed and performed; no residual tumor or positive lymph nodes were detected postoperatively. In 2 cases from the pT1 group (cases no. 6 and no. 8) lymphovascular invasion was present on final pathology -- both patients were sent for postoperative adjuvant chemoradiotherapy (long course radiotherapy with 5 FU based chemotherapy). One of them (case no. 6) was lost to follow-up.

All 6 patients in the pT2 group were offered adjuvant chemoradiotherapy or immediate radical surgery. An 88-year-old man (case no. 7) refused any other therapy or surveillance. Three patients (cases no. 1, 3, 5) were treated with adjuvant chemoradiotherapy. Cases no. 13 and 16 underwent immediate abdominoperineal resection -- no residual tumor or positive lymph nodes were detected postoperatively.

Patients were followed up from 2 to 35 months (median: 21 months). One patient (case no. 6) was lost to follow-up. There was one local recurrence (5%) in a patient (case no. 8) who refused to undergo abdominoperineal excision for T1 low rectal cancer, had unfavorable histology after TEM, and for which reason underwent postoperative chemoradiation. The patient underwent abdominoperineal resection 7 months after TEM (rpT2N0M0). The rest of the patients are alive and disease-free.

Discussion {#S0005}
==========

The management of early rectal cancer aims to offer a cure while minimizing the morbidity and mortality of the treatment. Total mesorectal excision is a gold standard today for rectal cancer treatment in terms of local control, prevention of distal spread and long-term survival, but may result in permanent stoma and a significant chance of sexual or urinary dysfunction (up to 40%), anastomotic leakage (5--10%) and long-term functional bowel disturbance \[[@CIT0009]\]. The TEM may offer the opportunity of cure with less detriment.

Standard TEM equipment was used in our series. However, to overcome high costs, a 'glove port' and standard laparoscopic instruments can be utilized \[[@CIT0010], [@CIT0011]\]. When performing TEM, determination of the peritoneal reflection is important to avoid injury to the bowel. However, the location and length of the peritoneal reflection are highly variable \[[@CIT0012]\].

There was one perforation of the abdominal cavity in our study, which was closed with double layer suture. No complications were detected afterwards -- this is in agreement with Morino *et al*. \[[@CIT0013]\], who in their recent study reported no influence of peritoneal perforation during TEM short-term or oncologic outcomes.

The successful treatment of rectal carcinoma by TEM depends on careful patient selection. Correct staging by imaging is crucial to define patient eligibility: MRI is useful to assess the nodal disease \[[@CIT0014]\], whereas endorectal ultrasound scan has a sensitivity of \> 80% and a specificity of \> 90% for T-staging \[[@CIT0015]\]. Nevertheless, endorectal ultrasound is a very user-dependent method and can result in inaccurately staged rectal cancer (up to 44.8% of tumors as reported in a study based on the UK TEM database \[[@CIT0016]\]).

Accepted low-risk criteria of T1 rectal carcinoma suitable for local treatment are well or moderately differentiated lesion, slight carcinoma invasion of the muscularis mucosa (sm1), smaller than 3 cm in diameter, less than 40% wall circumference and no sign of lymphovascular invasion \[[@CIT0005], [@CIT0017], [@CIT0018]\]. In a study based on an international multicentre TEM registry, Bach *et al*. \[[@CIT0019]\] defined three histopathological variables, which independently predict local recurrence-free survival: depth of tumor invasion (a composite of pT and Sm category), maximum tumor diameter and presence of intramural lymphovascular invasion.

The surgical margin status has a significant influence on the success of treatment: R1, Rx, R ≤ 1 mm or high-risk T1 rectal tumors increase the local recurrence rate from 6% to 39%. However, immediate radical surgery after non-radical local excision of rectal pT1 carcinoma reduces the recurrence rate to 6% \[[@CIT0020]\].

As for transanal excision in pT2 lesions, local therapy alone is related to high risk of local recurrence: overall recurrence rates (including patients who did and did not have chemoradiation) range from 6% to 18% \[[@CIT0021]\]. Our strategy in the current series was not to leave a single patient without further treatment if pT2 cancer was found in the final histology.

Lezoche *et al*. \[[@CIT0022]\] compared endoluminal locoregional resection by TEM to laparoscopic TME for T2 rectal cancer after chemoradiotherapy. They concluded that the probability of developing recurrence or metastases and cancer-related survival rate were similar in both groups. However, short-term results significantly favored TEM in terms of operating time, stoma rate, blood loss and transfusions, need for analgesia and hospital stay.

Ongoing trials (local excision versus TME in downstaged T2/T3 low rectal cancer after radiochemotherapy; neoadjuvant chemoradiation and local excision for uT2uN0) will help to answer the question concerning the treatment of higher rectal cancer stages by the local technique after neoadjuvant therapy \[[@CIT0023]\].

Conclusions {#S0006}
===========

In our hands, TEM was an alternative to standard total mesorectal excision in patients with low-risk early rectal cancer. Further follow-up is necessary to evaluate recurrence and survival rates after TEM for patients with invasive rectal cancer.
